- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
LENZ Therapeutics Inc (LENZ)
4.71
-0.20(-4.07%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.68
4.88
52 wk Range
4.54
50.40
LENZ Income Statement
Featured here, the Income Statement (earnings report) for LENZ Therapeutics Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
| Period Ending: | 2021 31/12 | 2022 31/12 | 2023 31/12 | 2024 31/12 | 2025 31/12 | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | - | 15 | - | - | 19.09 | |||||||||||||||||||||||||||||
Total Revenues Growth | - | - | - | - | - | |||||||||||||||||||||||||||||
Cost Of Revenues | - | - | - | - | 0.42 | |||||||||||||||||||||||||||||
Gross Profit | - | 15 | - | - | 18.67 | |||||||||||||||||||||||||||||
Gross Profit Growth | - | - | - | - | - | |||||||||||||||||||||||||||||
Gross Profit Margin % | - | 100% | - | - | 97.81% | |||||||||||||||||||||||||||||
Other Operating Expenses, Total | 6.69 | 25.48 | 72.43 | 58.61 | 109.81 | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||
Operating Income | -6.69 | -10.48 | -72.43 | -58.61 | -91.14 | |||||||||||||||||||||||||||||
Operating Income Growth | - | -56.6% | -590.92% | +19.08% | -55.5% | |||||||||||||||||||||||||||||
EBIT Margin % | - | -69.89% | - | - | -477.46% | |||||||||||||||||||||||||||||
Net Interest Expenses | - | 0 | 2.19 | 8.55 | 9.76 | |||||||||||||||||||||||||||||
Net Interest Expenses Growth | - | - | +54,625% | +290.73% | +14.07% | |||||||||||||||||||||||||||||
Interest Expense, Total | - | - | - | - | - | |||||||||||||||||||||||||||||
Interest And Investment Income | - | 0 | 2.19 | 8.55 | 9.76 | |||||||||||||||||||||||||||||
Other Non Operating Expenses, Total | -0.87 | 0.02 | 0.09 | 0.29 | -0.24 | |||||||||||||||||||||||||||||
EBT, Excl. Unusual Items | -7.56 | -10.46 | -70.15 | -49.77 | -81.63 | |||||||||||||||||||||||||||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||||||||||||||||||||||||||
Other Unusual Items, Total | - | - | - | - | - | |||||||||||||||||||||||||||||
EBT, Incl. Unusual Items | -7.56 | -10.46 | -70.15 | -49.77 | -81.63 | |||||||||||||||||||||||||||||
EBT, Incl. Unusual Items Growth | - | -38.36% | -570.37% | +29.05% | -64.01% | |||||||||||||||||||||||||||||
EBT, Incl. Unusual Items Margin | - | -69.76% | - | - | -427.62% | |||||||||||||||||||||||||||||
Income Tax Expense | - | 0.35 | -0.18 | 0 | 0.5 | |||||||||||||||||||||||||||||
Net Income to Company | -7.56 | -10.81 | -69.97 | -49.77 | -82.13 | |||||||||||||||||||||||||||||
Minority Interest | - | - | - | - | - | |||||||||||||||||||||||||||||
Net Income | -7.56 | -10.81 | -69.97 | -49.77 | -82.13 | |||||||||||||||||||||||||||||
Net Income Growth | - | -42.95% | -547.19% | +28.87% | -65.02% | |||||||||||||||||||||||||||||
Net Income Margin % | - | -72.07% | - | - | -430.25% | |||||||||||||||||||||||||||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||||||||||||||||||||||||||
Net Income to Common Excl. Extra Items | -7.56 | -10.81 | -69.97 | -49.77 | -82.13 | |||||||||||||||||||||||||||||
Basic EPS - Continuing Operations | -0.81 | -1.14 | -35.71 | -2.34 | -2.85 | |||||||||||||||||||||||||||||
Basic EPS - Continuing Operations Growth | - | -41.46% | -3,023.62% | +93.45% | -21.88% | |||||||||||||||||||||||||||||
Diluted EPS - Continuing Operations | -0.81 | -1.14 | -35.71 | -2.34 | -2.85 | |||||||||||||||||||||||||||||
Diluted EPS - Continuing Operations Growth | - | -41.46% | -3,023.62% | +93.45% | -21.88% | |||||||||||||||||||||||||||||
Basic Weighted Average Shares Outstanding | 9.36 | 9.46 | 1.96 | 21.28 | 28.81 | |||||||||||||||||||||||||||||
Diluted Weighted Average Shares Outstanding | 9.36 | 9.46 | 1.96 | 21.28 | 28.81 | |||||||||||||||||||||||||||||
Dividend Per Share | - | - | - | - | - | |||||||||||||||||||||||||||||
Dividend Per Share Growth | - | - | - | - | - | |||||||||||||||||||||||||||||
EBITDA | -6.69 | -10.48 | -72.41 | -58.55 | -90.85 | |||||||||||||||||||||||||||||
EBITDA Growth | - | -56.53% | -591.3% | +19.14% | -55.16% | |||||||||||||||||||||||||||||
EBITDA Margin % | - | -69.83% | - | - | -475.96% | |||||||||||||||||||||||||||||
EBIT | -6.69 | -10.48 | -72.43 | -58.61 | -91.14 | |||||||||||||||||||||||||||||
* In Millions of USD (except for per share items)
FAQ
What was LENZ Therapeutics’s revenue at year end?
At the end of the last reported fiscal year, LENZ Therapeutics (LENZ) recorded total revenue of 19.09 million USD.
How much revenue did LENZ Therapeutics report in the most recent quarter?
In its most recent quarterly earnings report, LENZ Therapeutics posted revenue of 5.49 million USD.
What was LENZ Therapeutics’s net income for the year?
For the full year, LENZ Therapeutics reported net income of -82.13 million USD.
How much net income did LENZ Therapeutics post in the last quarter?
In the most recent quarter, LENZ Therapeutics (LENZ) posted net income of -31.92 million USD.
What was LENZ Therapeutics’s gross profit for the year?
Gross profit for the year was reported at 18.67 million USD.
How much gross profit did LENZ Therapeutics generate last quarter?
LENZ Therapeutics recorded gross profit of 5.21 million USD in its latest quarterly report.
What was LENZ Therapeutics’s annual operating income?
For the full year, LENZ Therapeutics (LENZ) reported operating income of -91.14 million USD.
What was LENZ Therapeutics’s operating income last quarter?
Quarterly operating income was -34.17 million USD.
What was LENZ Therapeutics’s quarterly EBITDA?
In the latest quarter, EBITDA was reported at -34.06 million USD.
What was the quarter-over-quarter change in EBITDA for LENZ Therapeutics?
EBITDA changed by 22.63% million USD compared to the last quarter.
What is LENZ Therapeutics’s most recent gross profit margin?
The latest reported gross profit margin for LENZ Therapeutics (LENZ) is 94.90% million USD.
What is LENZ Therapeutics’s most recent net income margin?
Net income margin based on recent financials is -581.81% million USD.
What is LENZ Therapeutics’s most recent EBIT margin?
LENZ Therapeutics reported an EBIT margin of -622.89% million USD based on current figures.
How did LENZ Therapeutics’s revenue change compared to the previous quarter?
Revenue changed by 188.58% million USD compared to the prior quarter.
What was the quarter-over-quarter change in gross profit for LENZ Therapeutics?
In the latest quarter, gross profit changed by 531.03% million USD from the previous quarter.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.